An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cue Health to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cue Health (NASDAQ: HLTH), a healthcare technology firm, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference scheduled for January 11, 2022, at 5:15 p.m. Eastern Time. This presentation will be accessible via a live audio webcast on their website for 30 days post-event. Cue Health focuses on providing lab-quality diagnostics and real-time health information, revolutionizing home health management.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)-- Cue Health (“Cue”) (Nasdaq:HLTH), a healthcare technology company, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. Eastern Time.
A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at: www.cuehealth.com.
About Cue Health Cue Health (Nasdaq:HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India'sCentral Drugs Standard Control Organisation, and PSAR authorization from Singapore'sHealth Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
